All Stories

  1. PGx-Based in silico Analyses Identifies the Interactive Role of Genes, Glucose Metabolism and Dopaminergic Dysfunctional Pathways with Chronic Cocaine use and Misuse

    Article • Current Neuropharmacology, August 2026, Bentham Science Publishers

    Prof. Abdalla Bowirrat, Alireza Sharafshah, Professor kenneth Blum, Rajendra Badgaiyan

  2. Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety

    Article • Current Pharmaceutical Biotechnology, March 2026, Bentham Science Publishers

    Prof. Abdalla Bowirrat, Professor kenneth Blum, Prof. Sergio Schmidt, Professor Aviv Weinstein, ROSSANO FIORELLI, Rajendra Badgaiyan, Alireza Sharafshah

  3. In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder

    Article • Current Neuropharmacology, July 2025, Bentham Science Publishers

    Alireza Sharafshah, Professor kenneth Blum, Prof. Sergio Schmidt, Rajendra Badgaiyan, ROSSANO FIORELLI, Prof. Abdalla Bowirrat

  4. Using science to fix addiction forever - Reward Deficiency Syndrome Solutions

    Article • Current Pharmaceutical Biotechnology, January 2024, Bentham Science Publishers

    Professor kenneth Blum, Rajendra Badgaiyan, ELIZABETH GILLEY, Prof. Abdalla Bowirrat

  5. Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior

    Article • Current Pharmaceutical Biotechnology, August 2023, Bentham Science Publishers

    Professor kenneth Blum

  6. Epigenetic Effects of Psychoactive Drugs

    Article • Current Pharmaceutical Design, August 2023, Bentham Science Publishers

    Professor kenneth Blum, Rania Ahmed

  7. Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression

    Article • Current Psychopharmacologye, April 2022, Bentham Science Publishers

    Professor kenneth Blum, Rajendra Badgaiyan, Marjorie Gondre-Lewis, Prof. Abdalla Bowirrat

  8. Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic

    Article • Current Psychopharmacologye, June 2021, Bentham Science Publishers

    Professor kenneth Blum, Rajendra Badgaiyan, Prof. Abdalla Bowirrat

  9. Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise

    Article • Current Psychopharmacologye, June 2021, Bentham Science Publishers

    Bernard Downs, Professor kenneth Blum, Rajendra Badgaiyan, DR DEBASIS BAGCHI

  10. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine

    Article • Current Neuropharmacology, July 2020, Bentham Science Publishers

    Professor kenneth Blum, Marjorie Gondre-Lewis

  11. Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-Induced Hyperalgesia.

    Article • Current Psychopharmacologye, June 2020, Bentham Science Publishers

    Professor kenneth Blum, Rajendra Badgaiyan

  12. Hypodopaminergia and “Precision Behavioral Management” (PBM): It is a Generational Family Affair

    Article • Current Pharmaceutical Biotechnology, May 2020, Bentham Science Publishers

    Marjorie Gondre-Lewis, Professor kenneth Blum, Rajendra Badgaiyan, Bernard Downs

  13. In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The “Holy Grail” in Genetic Addiction Risk Testing

    Article • Current Psychopharmacologye, April 2020, Bentham Science Publishers

    Professor kenneth Blum

  14. The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis

    Article • Current Pharmaceutical Design, February 2018, Bentham Science Publishers

    Rajendra Badgaiyan, Professor kenneth Blum, Professor Zsolt Demetrovics

  15. Buprenorphine and Naloxone Combinations and Dopamine

    Article • Current Psychopharmacologye, January 2018, Bentham Science Publishers

    Professor kenneth Blum, Rajendra Badgaiyan, Lyle Fried

  16. OMICS

    Article • April 2016, Taylor & Francis

    Professor kenneth Blum

  17. Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior

    Article • Oncotarget, April 2016, Impact Journals, LLC

    Professor kenneth Blum

  18. The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity

    Article • Neuropsychopharmacology, March 2016, Nature

    Professor kenneth Blum

  19. Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics

    Article • Cureus, October 2015, Cureus, Inc.

    Professor kenneth Blum

  20. A Shared Molecular and Genetic Basis for Food and Drug Addiction

    Article • Psychiatric Clinics of North America, September 2015, Elsevier

    Professor kenneth Blum

  21. Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients

    Article • PLOS One, August 2015, PLOS

    Professor kenneth Blum

  22. miRegulome: a knowledge-base of miRNA regulomics and analysis

    Article • Scientific Reports, August 2015, Nature

    Professor kenneth Blum, Dr Vasco Azevedo

  23. Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: Role of enhanced brain reward functional connectivity and homeostasis redeeming joy

    Article • Journal of Behavioral Addictions, June 2015, Akademiai Kiado

    Professor kenneth Blum

  24. Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?

    Article • Expert Opinion on Biological Therapy, May 2015, Informa Healthcare

    Professor kenneth Blum

  25. Neurogenetic and Epigenetic Correlates of Adolescent Predisposition to and Risk for Addictive Behaviors as a Function of Prefrontal Cortex Dysregulation

    Article • Journal of Child and Adolescent Psychopharmacology, May 2015, Mary Ann Liebert Inc

    Professor kenneth Blum

  26. Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?

    Article • Molecular Neurobiology, March 2015, Springer Science + Business Media

    Professor kenneth Blum

  27. Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric

    Article • Journal of Behavioral Addictions, September 2014, Akademiai Kiado

    Professor kenneth Blum

  28. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia

    Article • Neuropsychiatric Disease and Treatment, October 2010, Taylor & Francis

    Professor kenneth Blum, Marlene Oscar-Berman

  29. Attention-deficit-hyperactivity disorder and reward deficiency syndrome

    Article • Neuropsychiatric Disease and Treatment, November 2008, Dove Medical Press

    Professor kenneth Blum, Marlene Oscar-Berman

  30. Preface

    Article • January 1977, Elsevier

    Professor kenneth Blum